Therefore, due to its ability to circumvent DNA damage and its role in DDR (and resolution of replicative stress), targeting TLS Polκ either pharmacologically or genetically may provide an alternative to GBM patients undergoing TMZ chemotherapy [74,75]. The gene discussed is POLK; the disease is glioblastoma.